Fibrocell Science — Investor Presentation (May 2019)
22 slides from Fibrocell Science's investor presentation, May 29, 2019
Slide 1: Corporate Presentation May 29, 2019
Corporate Presentation May 29, 2019
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this pu
Slide 3: Company Highlights
Company Highlights • Focus on Rare Skin Diseases . Medical breakthroughs for rare diseases of the skin and connective tissue with no approved therapies . Significant mortality and morbidity impact on pediatric populations . Proprietary autologous fibroblast platform derived from skin as the vehicle
Slide 4: Development Pipeline
Development Pipeline Program Condition Target Research Pre-Clinical Phase 1/2 Phase 3 FDA Designations Orphan Drug FCX-007 Recessive Dystrophic Type VII Rare Pediatric Disease Epidermolysis Bullosa Collagen Fast Track (RDEB) RMAT Orphan Drug FCX-013 Moderate to Severe Localized Scleroderma MMP-1 Rar
Slide 5: Our Platform Approach
Our Platform Approach Autologous fibroblasts Lentiviral • Delivery vehicle to shuttle target genes to the area of disease Fibroblast Delivery Vehicle Vector • Readily sourced, as fibroblasts are the most common cell type in skin and Vector connective tissue • An autologous approach has reduced rejec
Slide 6: Personalized Gene Therapy Approach
Personalized Gene Therapy Approach 6
Slide 7: Cell Manufacturing Experience
Cell Manufacturing Experience • Fibrocell’s existing cGMP cell therapy manufacturing facility in Exton, PA has been designated as the production site for FCX-007 and FCX-013 . ~13,000 square foot facility includes cleanroom manufacturing, cryogenic storage, QC laboratories and shipping/receiving are
Slide 8: FCX-007 – Recessive Dystrophic Epidermolysis Bullosa
FCX-007 – Recessive Dystrophic Epidermolysis Bullosa FCX-007 is a dermal fibroblast transduced with a lentiviral (LV) vector encoded with the gene for type VII collagen (COL7) Orphan Drug Designation Rare Pediatric Disease Designation Fast Track Designation Regenerative Medicine Advanced Therapy Des
Slide 9: About RDEB
About RDEB Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a monogenic disease resulting in chronic skin blistering and wounding Disease Current Treatments Epidemiology • Cause: A mutation in the • Current treatments only Dystrophic EB (DEB) COL7A1 gene that address symptoms ~5,500 – 12,500 US3
Slide 10: Interim Phase 1/2 Data Update
Interim Phase 1/2 Data Update Dosing Parameters Number of adult patients dosed 5 Patient age range 20 - 37 Number of wounds treated 8 Wound size range (cm2) 4.4 - 23.2 Cell dose concentration range (cells/mL) 1.0 x 107 - 2.7 x 107 • Performed on an outpatient basis using conscious sedation rather th
Slide 11: FCX-007 Interim Readout: Wound Closure
FCX-007 Interim Readout: Wound Closure The proportion of wounds healing at increasing closure percentages 12-week post-administration of a single injection session of FCX-007: Wound Closure % >50% >75% Complete Treated Control Wounds 88% (7/8) 75% (6/8) 63% (5/8) Untreated Control Wounds 29% (2/7) 1
Slide 12: Pharmacology: Immunofluorescence (IF)
Pharmacology: Immunofluorescence (IF) Patient A Patient B 332 - 1 1 Laminin - COL7 NC COL7 Merged with Merged stain nuclear 25 weeks 52 weeks 4 weeks 12 weeks 25 weeks 32 weeks* *following second injection at 25 weeks • COL7 expression continues to be detected in wounded and intact samples out to 52
Slide 13: Pharmacology: Immunoelectron Microscopy (IEM)
Pharmacology: Immunoelectron Microscopy (IEM) All images 25 weeks Post-Administration Samples labeled with LH24 mAb, specific to the NC-2 domain of the COL7 molecule COL7 Structure • COL7 expression continues to be detected in wounded and intact samples out to 52 weeks post-administration • Anchorin
Slide 14: DEFI-RDEB Phase 3 Clinical Trial Design
DEFI-RDEB Phase 3 Clinical Trial Design Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (DEFI-RDEB) • Open label, intra-patient design . Wounds pre-monitored prior to dosing to ensure they are non-healing . Fo
Slide 15: FCX-007 Co-Development Deal with Castle Creek Pharmaceuticals
FCX-007 Co-Development Deal with Castle Creek Pharmaceuticals • Under the terms of the collaboration agreement, Castle Creek will receive an exclusive license to commercialize FCX-007 in the United States . Castle Creek Pharmaceuticals is responsible for all commercialization activities for FCX-007
Slide 16: FCX-013 – Moderate to Severe Localized Scleroderma
FCX-013 – Moderate to Severe Localized Scleroderma FCX-013 is a dermal fibroblast transduced with a lentiviral (LV) vector encoded with the gene for MMP-1, under control of the RheoSwitch Therapeutic System® (RTS®) Orphan Drug Designation Rare Pediatric Disease Designation Fast Track Designation 16
Slide 17: About Localized Scleroderma
About Localized Scleroderma Disease Epidemiology • Excess production of collagen • Localized Scleroderma characterized by skin fibrosis ~160,000 sufferers US5 comprised of different sub- • Focus on moderate to severe types subtypes . ~90,000 patients are • Thickening may extend to considered moderat
Slide 18: FCX-013 Status
FCX-013 Status • Product profile . Dermal fibroblasts genetically modified using lentivirus and encoded for matrix metalloproteinase 1 (MMP-1), a protein responsible for breaking down collagen . Incorporates Intrexon’s RheoSwitch Therapeutic System® (RTS®) to control protein expression • Activated b
Slide 19: FCX-013 Phase 1/2 Clinical Trial Design
FCX-013 Phase 1/2 Clinical Trial Design A Phase 1/2 Trial of a Combination of FCX-013 (Genetically-Modified Human Dermal Title Fibroblasts) plus Veledimex for the Treatment of Moderate to Severe Scleroderma (Morphea) NCT03740724 Primary Objective To evaluate the safety of a single intradermal inject
Slide 20: FCX-013 Proof-of-Concept Study
FCX-013 Proof-of-Concept Study • Study Design D0 D28 D29 D39 . Bleomycin treated SCID mouse model . N=30 mice over test and control groups Blecomycin treatments Ligand Treatment . Assessed histologically for reduction of dermal thickness and sub-dermal muscle in the presence Cell Harvest skin of FCX
Slide 21: Milestones and Financials
Milestones and Financials Program Milestone Timing Hold Type B meeting with FDA 1Q2019 Report updated Phase 1/2 data 1Q2019 Initiate collaboration with Castle Creek Pharmaceuticals 2Q2019 Achieve RMAT designation 2Q2019 FCX-007 Initiate DEFI-RDEB Phase 3 clinical trial 2Q2019 Complete enrollment and
Slide 22: References
References 1 Fine, J. et. al. (ed.). Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the Findings of the National Epidermolysis Bullosa Registry. The John Hopkins University Press, Baltimore, MD, 1999. 2 The Dystrophic Epidermolysis Research Association of America (DebRA)